Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appeal
An appeal has been lodged for this appraisal. Below are the papers related to this appeal. More information on the Technology Appraisal Appeal Process can be found on the Appeals section of the NICE website.
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: background information on the technology appraisal
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: notice of appeal hearing
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appeal announcement
Renal cell carcinoma: appeal decision
This page was last updated: 02 July 2010